

Product Overview

For Antacids, Digestive Aids and Mineral Supplements

Making a difference to your product formulations

www.spipharma.com



Naturally Sourced Minerals

In the United States many of our Magnesium Hydroxide based products originate from the Delaware Bay. This location was chosen due to the excellent quality and salinity of the seawater. Prior to pumping the seawater to our facility, it is filtered by using the natural sand bed of the bay to ensure no water life is affected by our process.

SUSPENSIONS

Ingredients that save you time and money and provide excellent mouthfeel for your suspensions

* Assay; Tapped Density and PSD D50 (µm) are not specifications but typical values and range for our products

SOLID DOSAGE FORMS

	Commercial Name	Type	Assay*	Added Excipients	Tapped Density*	PSD D50(μm)*	API for		Process		Forms		Additional information
							Antacids	Digestive Aid	Wet Granulation	Direct Compression	Chewable Tablet	Instant Powder†	
MAGNESIUM COMPOUNDS													
Magnesium Hydroxide	5100 USP / 5101 EP	Powder	NLT 95% Mg(OH) ₂	-	0.6 - 0.9	35	•	•	■		◆		
Magnesium Hydroxide (Pre-formulated)	MS90	DC Powder	95% Mg(OH) ₂	Starch	0.8	150 - 170	•	•		■	◆	◆	Can be easily combined with CS90
SIMETHICONE					TappedDensity*								
Simethicone †	DC SIM 100	DC Powder	60-70%Simethicone	-	-	50		•		■	◆	◆	Can be combined with AHMH3535; CS90; MS90; CM90 and Vitasmooth for anti-flatulent properties
ALUMINUM COMPOUNDS					TappedDensity*								
Aluminum Hydroxide	0200 USP / 0201 EP	Powder	NLT 50% Al ₂ O ₃	-	0.16 - 0.25	12	•		■		◆		
	0325 USP / 0326 EP	Powder	NLT 50% Al ₂ O ₃	-	0.3 - 0.6	25	•		■		◆		
Aluminum Hydroxide (Pre-formulated)	Cremalin 0501	Powder	40% Al ₂ O ₃	Sorbitol	Hand Tapped 0.3 - 0.6	-	•		■	■	◆	◆	
ALUMINUM / MAGNESIUM COMPOUNDS					ApparentDensity*								
Magaldrate	7001 EP	Powder	NLT90%Magaldrate	-	0.3 - 0.4	40	•		■		◆		
Al Hyd / Mg Carbonate	AHMC 0611	Powder	42% Al ₂ O ₃ 8% MgO	-	NMT 0.2	micronized	•		■		◆		
	AHMC 0600	Powder	42% Al ₂ O ₃ 8% MgO	-	0.3 - 0.4	-	•		■		◆		
PRE-FORMULATED COMPOUNDS					TappedDensity*								
Co-Dried Powders (Al Hyd / Mg Hyd)	AHMH 3535	DC Powder	35%AlHyddriedgelUSP 35% Mg(OH) ₂	Sorbitol/Mannitol, Sucrose,Sodium Saccharin	NLT 0.6	100 - 120	•			■	◆	◆	400 mg Dried Al. Hyd. USP per tablet (or multiple) 400 mg Mg(OH) ₂ per tablet (or multiple)
CalciumCarbonate	CS90	DC Powder	90% CaCO ₃	Starch	0.85	150 - 175	•			■	◆	◆	Can be easily combined with MS90
	CM90	DC Powder	91% CaCO ₃	Maltodextrin	1.5	490 - 500	•			■	◆	◆	
	Vitasmooth	DC Powder	58% CaCO ₃	Dextrose,Sucrose, MCCMaltodextrin	0.8	150	•			■	◆	◆	Designed for meltaway chewable tablet

Directly Compressible Preformulated Mineral Ingredients for Supplements

SOLID DOSAGE FORMS

Our DC ingredients flow as smooth as milk allowing you to make either chewable tablets with excellent mouthfeel or easy to swallow tablets.

	Commercial Name	Type	Assay*	Added Excipients	Tapped Density*	PSD D50 (µm)*	Use As		Forms				Additional Information	
							Mineral Source	Excipient	Chewable Tablet	Swallow Tablet	Instant Powder ‡	Effervescent Tablet		
MAGNESIUM COMPOUNDS														
Magnesium Hydroxide	MS90	DC Powder	95% Mg(OH) ₂	Starch	0.8	150 - 170	•	•	■	■	■	■	Can be easily combined with CS90	
CALCIUM CARBONATE COMPOUNDS														
Calcium Carbonate	CS90	DC Powder	90% CaCO ₃	Starch	0.85	150 - 175	•	•	■	■	■	■	Can be easily combined with MS90	
	CM90	DC Powder	91% CaCO ₃	Maltodextrin	1.5	490 - 500	•	•	■	■	■	■	High density and compressibility Ideal for Swallow Tablets	
	Vitasmooth	DC Powder	58% CaCO ₃	Dextrose, Sucrose, MCC, Maltodextrin	0.8	150	•		■		■		Designed for meltaway chewable tablet	
SIMETHICONE														
Simethicone †	DC SIM 100	DC Powder	60 - 70% Simethicone	-	-	50		•				■	Anti-foaming agent for effervescent forms	

* Assay; Tapped Density and PSD D50 (µm) are not specifications but typical values and range for our products

† Currently available in MEA, LATAM and ASPAC regions

‡ Instant Powder: Take directly or pre-disperse in water

 SPI Pharma

 salesinfo@spipharma.com

 @spipharma

 www.spipharma.com

 SPI Pharma



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties.

SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.

May 2024
All rights reserved
© 2024 SPI Pharma